Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features
Research highlights
► Adjudication of all radiographs of consecutive patients with femoral fractures ► 96 of 906 (10.6%) patients had subtrochanteric fractures of which 63 were low-energy ► 10 of the 63 fractures were atypical or 1.1% of all femoral fractures ► Atypical fractures were more frequent among bisphosphonate users (OR 17.0) ► Half of the patients with atypical fractures had never used bisphosphonates
Introduction
Bisphosphonates (BPs) are the mainstay of treatment of osteoporosis, used by millions due to their proven efficacy in reducing fracture risk [1], [2]. In recent years case reports and case reviews of rather unusual fractures of the femur below the lesser trochanter (subtrochanteric or femoral shaft) have been reported in patients on long-term BP therapy [3], [4]. These fractures have been characterized by a specific radiographic pattern consisting of a simple, transverse or short oblique fracture with unicortical beaking in areas of thickened cortices, and have been designated as atypical [5], [6]. The apparent increasing frequency of these fractures, albeit still low in numbers, has attracted the attention of regulatory authorities and of the public at large.
Causality between atypical fractures and BPs is debatable [7], [8], [9], [10], [11], [12], [13]. To address this issue we reviewed all radiographs and treatment data from consecutive patients with femur fractures admitted to a single center over an 11-year period with the following specific aims: 1. To estimate the frequency of atypical fractures of the femur. 2. To examine the association between atypical fractures and BPs use. 3. To examine risk factors other than BPs potentially contributing to the risk of atypical fractures.
Section snippets
Study design
We performed a retrospective analysis of all patients aged ≥ 50 years consecutively admitted to our Institution for surgical repair of a new fracture of the femur between January 1997 and December 2007. This time frame was selected because alendronate was approved in the Netherlands for the treatment of osteoporosis in 1996. All patients were identified from hospital records using ICD-9-CM discharge codes. Radiographs of all patients were reviewed and fracture site was adjudicated and
Patients
Out of 1245 patients with a new fracture of the femur identified by ICD-9-CM discharge codes, 932 were ≥50 years (Fig. 1). Radiographs were available for review in 909 and examination of these radiographs led to exclusion of another 3 patients (one with a fracture of the acetabulum, one with Paget's disease and one with metastatic breast cancer). The final cohort consisted, thus, of 906 patients (29.4% men) with a mean age of 77.9 ± 10.5 years (range 50–99 years). Adjudication of the fracture site
Discussion
The present study, with adjudication of all radiographs of consecutive patients with femur fractures, was designed to assess the prevalence of atypical fractures and their association to BP use. In our cohort, the characteristics of the patients and the distribution of femur fractures were concordant with those reported in larger epidemiological studies in which ICD discharge codes were used for the identification of the fracture site [10], [16]. Miscoding has been previously reported in up to
Acknowledgments
We thank Ms N. Leyerzapf for her help in the initial acquisition of the data.
Financial Disclosures: S. E. Papapoulos has received consulting fees and/or honoraria from Alliance for Better Bone Health, Amgen, Eli Lilly, Merck & Co, Novartis, Pfizer, Roche/GSK, and Wyeth. He is a member of the Task Force of the American Society of Bone and Mineral Research and of the Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the International
References (28)
- et al.
Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies
Bone
(2010) - et al.
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
Injury
(2008) Bisphosphonates and atypical femoral fractures: a time for reflection
Maturitas
(2010)- et al.
Subtrochanteric stress fracture of the femur following total knee arthroplasty
J Arthroplasty
(1997) - et al.
Unilateral stress fracture of the femoral shaft combined with contralateral insufficiency fracture of the femoral shaft after bilateral total knee arthroplasty
J Orthop Sci
(2008) - et al.
Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series
PM R
(2010) Bisphosphonates for postmenopausal osteoporosis
- et al.
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
Osteoporos Int
(2008) Adverse effects of bisphosphonates
Calcif Tissue Int
(2010)- et al.
Low-energy femoral shaft fractures associated with alendronate use
J Orthop Trauma
(2008)